Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANOVA-4: TTFields + atezolizumab + gemcitabine + nab-paclitaxel in first-line mPDAC
2024-515407-19-00Phase 3Completed
- Sponsor
- NovoCure
- Start
- Oct 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 3, open-label, single-arm trial of atezolizumab, gemcitabine, nab-paclitaxel and Tumor Treating Fields in pancreatic adenocarcinoma (PDAC), sponsored by NovoCure. Primary endpoint: Disease control rate by RECIST v1.1. Started Oct 2024; status: completed.
02
Drugs
atezolizumabgemcitabinenab-paclitaxelTumor Treating Fields
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2024-515407-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515407-19-00.